TB-500 vs thymosin β4: what a 2026 scoping review mapped
Most of the healing literature is about full-length thymosin β4. Direct TB-500 human evidence is almost absent.
Online, TB-500 is often treated as interchangeable with thymosin β4, a 43-residue actin-binding peptide. A 2026 scoping review searched PubMed, Europe PMC and ClinicalTrials.gov through March 2026 to see what the literature actually covers.
What the review found
Of 1,772 records, 80 studies were included. Most evaluated thymosin β4, not TB-500. Common settings were wound/skin, vascular, ocular/cornea and bone. Direct tendon, ligament, muscle and cartilage papers were sparse. Human evidence clustered in cornea and wound studies of thymosin β4. Direct TB-500 evidence was limited to a single included study.
Why the names get mixed
TB-500 is typically described as a short synthetic fragment related to thymosin β4’s actin-binding region (often discussed as Ac-LKKTETQ). A fragment is not the same molecule as the parent peptide, and a parent-peptide cornea trial is not a musculoskeletal TB-500 trial.
Bottom line
Evidence ladder: Animal for TB-500 as sold in research markets; limited human pilot data exist for thymosin β4 in selected wound and eye settings. The 2026 map is useful because it shows how marketing collapsed two evidence bases into one name.
Sources
Educational content only — not medical advice. See our Medical disclaimer and Editorial policy.